Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) was upgraded by analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued on Saturday.

Several other brokerages have also recently commented on ELDN. Rodman & Renshaw began coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, July 21st. They issued a "buy" rating and a $12.00 target price for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Eledon Pharmaceuticals in a research report on Wednesday, June 24th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eledon Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $9.67.

Read Our Latest Stock Analysis on Eledon Pharmaceuticals

Eledon Pharmaceuticals Stock Performance

Shares of NASDAQ ELDN opened at $3.54 on Friday. Eledon Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $4.60. The stock has a market capitalization of $273.25 million, a P/E ratio of -3.89 and a beta of 0.98. The stock's fifty day moving average is $3.73 and its 200 day moving average is $3.28.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.11). Equities research analysts forecast that Eledon Pharmaceuticals will post -0.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Legal & General Group Plc acquired a new stake in shares of Eledon Pharmaceuticals during the 2nd quarter valued at $28,000. BNP Paribas Financial Markets increased its holdings in Eledon Pharmaceuticals by 143.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,154 shares of the company's stock worth $31,000 after purchasing an additional 7,166 shares in the last quarter. Millennium Management LLC acquired a new position in Eledon Pharmaceuticals in the 4th quarter worth about $36,000. Relyea Zuckerberg Hanson LLC bought a new position in Eledon Pharmaceuticals in the first quarter valued at about $37,000. Finally, Waverly Advisors LLC bought a new position in Eledon Pharmaceuticals in the first quarter valued at about $39,000. 56.77% of the stock is currently owned by institutional investors.

About Eledon Pharmaceuticals

(Get Free Report)

Eledon Pharmaceuticals, Inc NASDAQ: ELDN is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.

Read More

• Five stocks we like better than Eledon Pharmaceuticals
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA's $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eledon Pharmaceuticals Right Now?

Before you consider Eledon Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.

While Eledon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here